This implies that passive immunization with tau antibodies can be a viable therapeutic target and the CSF amount of p-tau262/356 or with the microtubule binding domain (MTBD) can function a useful biomarker of tau pathology to observe tau therapeutics in clinical trials. Initial, they tested this